Under this Small Business Innovation Research (SBIR) Phase I project, Research Topic 149, the Contractor shall develop predictive in vivo screening systems for phenotypic drug discovery for smoking cessation. The Contractor shall accomplish this through the following objectives: Objective 1- Evaluate a battery of tests aimed at examining various components of nicotine addiction to be used for phenotypic drug discovery and development of smoking cessation medications. Objective 2- Phenotypically profile four FDA approved smoking cessation drugs (varenicline, bupropion, clonidine and nortriptyline, each tested at three doses) and two controls (positive drug at an appropriate dose and negative with vehicle) using the behavioral tests/assays validated in Objective 1.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research – Phase I (N43)
Project #
271201300037C-0-0-1
Application #
8756315
Study Section
Project Start
2013-08-30
Project End
2014-08-29
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$338,884
Indirect Cost
Name
Afasci, Inc.
Department
Type
DUNS #
160127655
City
Redwood City
State
CA
Country
United States
Zip Code
94063